EZH2 and Miyoshi myopathy: Though these initial pre-clinical results on the use of EZH2 inhibitors in MM are encouraging, some reports also demonstrate that MM cells can develop resistance to such inhibitors like tazemetostat (EPZ-6438) through epigenetic mechanisms75.